Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
PHILADELPHIA, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), today announced the signing of a license with Stanford University providing exclusive rights to certain breakthrough gene therapy technologies developed in the labs of Professor Mark A. Kay, M.D., Ph.D., Dennis Farrey Family Professor in Pediatrics, Professor of Genetics, at Stanford University School of Medicine. Under the license, Medgenics gains the exclusive right for the autologous ex vivo use of Stanford’s GeneRide novel promoter-less gene therapy technology in combination with Medgenics’ proprietary TARGTTM technology. Medgenics also receives the exclusive right to use this technology for the delivery of hematopoietic stem cells for sickle cell anemia and beta thalassemia.
“We are excited to gain access to the GeneRide technology, combining the benefits of AAV vector gene transfer with the potential for permanent delivery of therapeutic proteins and peptides,” said Garry Neil, MD, Chief Scientific Officer of Medgenics. “Most importantly, this system is designed to allow efficient and predictable integration into precisely defined sites, using naturally occurring promoters.”
“By avoiding off-target integration the GeneRide system could provide a comparably safer approach than other competing gene therapies,” said Mike Cola, Medgenics CEO. “The additional capabilities afforded by the Stanford technology puts us in a position to be a leader in ex vivo gene therapy.”
About Medgenics, Inc.
Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is the developer of TARGTTM (Transduced Autologous Restorative Gene Therapy), a proprietary platform for the sustained production and delivery of therapeutic proteins, monoclonal antibodies and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases. For more information, visit the Company's website at www.medgenics.com.
Contacts: Medgenics, Inc.: John Leaman [email protected] Brian Piper [email protected] Stern Investor Relations: Beth DelGiacco 212-362-1200 [email protected]
